{"entity":{"id":"solange-peters","kind":"person","name":"Solange Peters","aka":[],"tldr":"Solange Peters is a lung cancer trialist and past ESMO President who led CheckMate 743 in mesothelioma.","summary":"Solange Peters is Head of Medical Oncology at Lausanne University Hospital (CHUV), working alongside the Ludwig Institute Lausanne, and served as President of the European Society for Medical Oncology (ESMO) in 2020-2021. Her specialisms are thoracic oncology, immunotherapy and mesothelioma. She led CheckMate 743, the Lancet trial of first-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma. Her work spans mesothelioma and non-small-cell lung cancer, and her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Peters%20S%5BAuthor%5D%20mesothelioma%20nivolumab"}],"tags":[],"related":[],"cancers":["mesothelioma","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["esmo","chuv-lausanne"],"pathways":[],"terms":[],"trials":["checkmate-743"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Oncology, Lausanne University Hospital (CHUV); ESMO President 2020-2021","institutionId":"esmo","specialisms":["Thoracic oncology","Immunotherapy","Mesothelioma"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Peters%20S%5BAuthor%5D%20mesothelioma%20nivolumab"}],"papers":[{"title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(20)32714-8"}]},"route":"/people/solange-peters/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/"},{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","route":"/institutions/chuv-lausanne/"}],"trial":[{"id":"alex","kind":"trial","name":"ALEX","route":"/trials/alex/"},{"id":"checkmate-743","kind":"trial","name":"CheckMate 743","route":"/trials/checkmate-743/"}],"paper":[{"id":"paper-peters-alex-alectinib-crizotinib-nejm-2017","kind":"paper","name":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/"},{"id":"paper-codebreak-200-lancet-2023","kind":"paper","name":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","route":"/key-papers/paper-codebreak-200-lancet-2023/"}],"company":[{"id":"etop-ibcsg","kind":"company","name":"ETOP IBCSG Partners Foundation","route":"/companies/etop-ibcsg/"}]}}